Minimally Invasive Ablative Therapies for Definitive Treatment of Localized Prostate Cancer in the Primary Setting
Prostate Cancer · 2011
DOI: 10.1155/2011/394182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prostate Cancer, 2011. Verfasst von Eugene W Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, New York University School of Medicine, NY 10016, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Traditionally, the patient with a new diagnosis of localized prostate cancer faces either radical therapy, in the form of surgery or radiation, or active surveillance. A growing subset of these men may not be willing to accept the psychological burden of active surveillance nor the side effects of extirpative or radiation therapy. Local ablative therapies including cryotherapy, high-intensity focused ultrasound, and vascular-targeted photodynamic therapy have emerged as a means for minimally invasive definitive treatment. These treatments are well tolerated with decreased morbidity in association with improvements in technology; however, long-term oncologic efficacy remains to be determined.
Autor:innen und Institutionen
- Department of Urology, New York University School of Medicine, NY 10016, USA.
Zitieren
APA
Lee, E. W., & Huang, W. C. (2011). Minimally Invasive Ablative Therapies for Definitive Treatment of Localized Prostate Cancer in the Primary Setting. Prostate Cancer. https://doi.org/10.1155/2011/394182
Vancouver
Lee EW, Huang WC. Minimally Invasive Ablative Therapies for Definitive Treatment of Localized Prostate Cancer in the Primary Setting. Prostate Cancer. 2011. doi:10.1155/2011/394182
BibTeX
@article{Lee2011,
author = {Lee, Eugene W and Huang, William C},
title = {Minimally Invasive Ablative Therapies for Definitive Treatment of Localized Prostate Cancer in the Primary Setting},
journal = {Prostate Cancer},
year = {2011},
doi = {10.1155/2011/394182}
}
EUVIMED